Anti‑CD34 CE/IVD antibodies enable robust immunohistochemical detection of hematopoietic progenitor and endothelial cell populations in formalin‑fixed, paraffin‑embedded (FFPE) tissues. These antibodies are integral in hematopathology for precise disease classification, blast cell assessment, and evaluation of marrow and vascular components.
Biological Significance of CD34
- Transmembrane sialomucin: CD34 is a transmembrane phosphoglycoprotein expressed on early hematopoietic stem and progenitor cells, mediating cell–cell adhesion and interactions with the bone marrow niche.
- Progenitor and endothelial expression: Beyond hematopoietic cells, CD34 is present on vascular endothelial cells and other progenitor subsets, reflecting its involvement in multipotent lineages and vascular biology.
Diagnostic Utility in Hematopathology
- Blast identification in leukemias: CD34 IHC highlights immature blast populations, facilitating differentiation of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) based on lineage and maturation stage.
- Prognostic relevance: In AML, CD34 expression often marks primitive blasts and may correlate with more aggressive disease; in ALL, positivity denotes early lymphoid precursors with distinct clinical features.
- Marrow and vascular assessment: CD34 staining supports quantification of blasts, evaluation of vascular density, and distinction between hematopoietic and non‑hematopoietic elements in complex tissue samples.
Key Features of CD34 CE/IVD Antibodies
- Regulatory compliance: CE/IVD‑marked for validated in vitro diagnostic use in FFPE human tissues.
- Specificity and performance: Well-characterized clones (e.g., QBEnd‑10) deliver strong membranous staining with optimized antigen retrieval. Interpretation should be performed by qualified professionals.
- Quality and reproducibility: Optimized for sensitivity and specificity in routine pathology workflows, ensuring consistent and reliable results across laboratories.
